ARCHIVES

Weak Structure, Deficiencies, Cited In Dana-Farber Reviews

This article is from The Cancer Letter archive.

Vol. 21 No. 42 | November 3, 1995

Download PDF Visit The Full Archive

Related Articles

Capitol Hill: Senate bill would allow sale of therapies for catastrophic illness after phase I trials.

December 2, 2005

Bristol-Lyers Squibb, Axion In Joint Venture To Sell Oncology Drugs to Office-Base Practices

September 3, 1993

Cancer Meetings Listed

April 15, 1994

Senate Subcommittee Seeking $2 Billion In for NIH, Bumps Up Against Caps

June 25, 1999

Chemo+Radiation Preserves Voice, RTOG Study Finds

December 26, 2003

ImClone: Waksals To Pay $5 Million To Settle With SEC.

January 28, 2005